Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 3/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7266907 | 0.89 | CHRM1 (0.49) | CHRM1CHRM2CHRM4CHRM3 | |
| Oxalic Acid SCHEMBL10367531 | 0.88 | CHRM1 (0.45) | CHRM1CHRM2CHRM4CHRM3 | |
| SCHEMBL10369501 | 0.87 | CHRM1 (0.51) | CHRM1CHRM2CHRM4CHRM3 | |
| SCHEMBL6965129 | 0.79 | CHRM2 (0.47) | CHRM1CHRM2CHRM4CHRM3 | |
| Hydrochloric Acid SCHEMBL5200635 | 0.78 | ALDH1A1 (0.49) | CHRM1CHRM2CHRM4CHRM3 | |
| SCHEMBL10569876 | 0.77 | CHRM1 (0.33) | CHRM1CHRM2CHRM4CHRM3 | |
| Hydrochloric Acid SCHEMBL10567916 | 0.76 | ALDH1A1 (0.36) | CHRM1CHRM2CHRM4CHRM3 | |
| SCHEMBL9374098 | 0.76 | EPHX1 (0.36) | CHRM1CHRM2CHRM4CHRM3 | |
| SCHEMBL10570225 | 0.71 | ALDH1A1 (0.41) | — | |
| SCHEMBL10368013 | 0.70 | CHRM2 (0.41) | CHRM1CHRM2CHRM4CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4870081-A | DEMENTIA | BEECHAM GROUP P.L.C. (GB) | 1989-09-26 | — | — | US | claimed |
| EP-0257741-A2 | Azabicyclic compounds, process and intermediates for their preparation and pharmaceutical compositions containing them | BEECHAM GROUP PLC (GB) | 1988-03-02 | — | — | EP | claimed |
| US-8367696-B2 | Aza-bridged-ring compound | ASTELLAS PHARMA INC. (JP) | 2013-02-05 | — | — | US | disclosed |
| US-8367696-B2 | Aza-bridged-ring compound | ASTELLAS PHARMA INC. (JP) | 2013-02-05 | — | — | US | disclosed |
| US-8367696-B2 | Aza-bridged-ring compound | ASTELLAS PHARMA INC. (JP) | 2013-02-05 | — | — | US | disclosed |
| US-20100105658-A1 | AZA-BRIDGED-RING COMPOUND | ASTELLAS PHARMA INC. (JP) | 2010-04-29 | — | — | US | disclosed |
| US-20100105658-A1 | AZA-BRIDGED-RING COMPOUND | ASTELLAS PHARMA INC. (JP) | 2010-04-29 | — | — | US | disclosed |
| US-20100105658-A1 | AZA-BRIDGED-RING COMPOUND | ASTELLAS PHARMA INC. (JP) | 2010-04-29 | — | — | US | disclosed |
| EP-2119716-A1 | AZA-BRIDGED-RING COMPOUND | Astellas Pharma Inc. (JP) | 2009-11-18 | — | — | EP | disclosed |
| US-5405853-A | Potent muscarinic agonists having good central nervous system penetrability | MERCK SHARPE & DOHME LTD. (GB) | 1995-04-11 | — | — | US | disclosed |
| EP-0307142-B1 | Thiadiazoles useful in the treatment of senile dementia | MERCK SHARP & DOHME (GB) | 1994-09-14 | — | — | EP | disclosed |
| EP-0239309-B1 | Oxadiazoles useful in the treatment of senile dementia | MERCK SHARP & DOHME (GB) | 1994-01-12 | — | — | EP | disclosed |
| EP-0307142-A1 | Thiadiazoles useful in the treatment of senile dementia | MERCK SHARP & DOHME LTD. (GB) | 1989-03-15 | — | — | EP | disclosed |
| EP-0257741-A2 | Azabicyclic compounds, process and intermediates for their preparation and pharmaceutical compositions containing them | BEECHAM GROUP PLC (GB) | 1988-03-02 | — | — | EP | disclosed |
| EP-0239309-A2 | Oxadiazoles useful in the treatment of senile dementia | MERCK SHARP & DOHME LTD. (GB) | 1987-09-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105658-A1 | AZA-BRIDGED-RING COMPOUND | CHRM3, CHRM1, CHRM2 | CHRM1 2/4885CHRM2 3/4885CHRM4 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.